Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Trial details
- Registry ID
- NCT05501886
- Phase
- Phase 3
The FDA approved Gedatolisib (PF-05212384) on 14 Jul 2026.
Drug identity checked against registry records
Also recorded as PF-05212384; PKI-587
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)NCT05501886 | CELC | Phase 3 | Active not recruiting | 2026-06-30Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-07-14Day | Gedatolisib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA219908", "applicant_as_listed_by_fda": "CELCUITY", "brand_names": ["REVTORPYK"], "active_ingredients": ["GEDATOLISIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20260714", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |